Published in Cardiorenal Med on April 18, 2012
The impact of comorbidity on cancer survival: a review. Clin Epidemiol (2013) 1.68
The role of prostatitis in prostate cancer: meta-analysis. PLoS One (2013) 0.98
Obesity, diabetes and aggressive prostate cancer hormone-naïve at initial diagnosis. Cent European J Urol (2014) 0.92
Metformin as an adjuvant drug against pediatric sarcomas: hypoxia limits therapeutic effects of the drug. PLoS One (2013) 0.85
Defects in mitophagy promote redox-driven metabolic syndrome in the absence of TP53INP1. EMBO Mol Med (2015) 0.85
Comorbidity in older adults with cancer. J Geriatr Oncol (2015) 0.85
Increased risk of cancer in patients with early-onset cataracts: a nationwide population-based study. Cancer Sci (2014) 0.80
Vascular stiffness in insulin resistance and obesity. Front Physiol (2015) 0.78
Adipocyte secreted factors enhance aggressiveness of prostate carcinoma cells. PLoS One (2015) 0.77
Concomitant Presence of Carcinoma of Breast in a Patient with Early-Onset Cataract: First Case Report of a Potential Association. J Clin Diagn Res (2017) 0.75
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med (2002) 101.79
Prevalence and trends in obesity among US adults, 1999-2008. JAMA (2010) 50.58
Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med (2003) 35.39
Banting lecture 1988. Role of insulin resistance in human disease. Diabetes (1988) 33.22
Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. Lancet (2009) 26.09
Bariatric surgery: a systematic review and meta-analysis. JAMA (2004) 23.34
Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet (2008) 20.62
Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med (2007) 18.45
Obesity. Lancet (2005) 17.67
Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer (2004) 16.69
C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA (2001) 15.85
Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. JAMA (2008) 13.69
Adipose tissue as an endocrine organ. J Clin Endocrinol Metab (2004) 11.94
Long-term mortality after gastric bypass surgery. N Engl J Med (2007) 10.75
Diabetes mellitus, fasting glucose, and risk of cause-specific death. N Engl J Med (2011) 10.33
Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol (2006) 10.05
Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes (1997) 8.96
Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus: four-year results of the Look AHEAD trial. Arch Intern Med (2010) 8.77
Physical activity and survival after breast cancer diagnosis. JAMA (2005) 8.60
Adiponectin and adiponectin receptors. Endocr Rev (2005) 8.46
Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med (1995) 7.62
Obesity, fat distribution, and weight gain as risk factors for clinical diabetes in men. Diabetes Care (1994) 7.11
Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch Intern Med (2001) 7.07
Guidelines for healthy weight. N Engl J Med (1999) 7.03
Causes of cancer in the world: comparative risk assessment of nine behavioural and environmental risk factors. Lancet (2005) 6.63
Dietary fat reduction and breast cancer outcome: interim efficacy results from the Women's Intervention Nutrition Study. J Natl Cancer Inst (2006) 6.41
The evolving diabetes burden in the United States. Ann Intern Med (2004) 6.36
Insulin-like growth factors and neoplasia. Nat Rev Cancer (2004) 6.29
Tumour necrosis factor and cancer. Nat Rev Cancer (2009) 6.27
Low-grade systemic inflammation and the development of type 2 diabetes: the atherosclerosis risk in communities study. Diabetes (2003) 5.43
The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer (2005) 5.07
Inflammation, a key event in cancer development. Mol Cancer Res (2006) 5.03
Fasting insulin and outcome in early-stage breast cancer: results of a prospective cohort study. J Clin Oncol (2002) 4.55
Body size and risk of colon and rectal cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC). J Natl Cancer Inst (2006) 4.17
Regional distribution of body fat, plasma lipoproteins, and cardiovascular disease. Arteriosclerosis (1990) 4.01
Hypertriglyceridemic waist: A marker of the atherogenic metabolic triad (hyperinsulinemia; hyperapolipoprotein B; small, dense LDL) in men? Circulation (2000) 3.78
Obesity and colon and rectal cancer risk: a meta-analysis of prospective studies. Am J Clin Nutr (2007) 3.66
Insulin and colon cancer. Cancer Causes Control (1995) 3.48
Within-trial cost-effectiveness of lifestyle intervention or metformin for the primary prevention of type 2 diabetes. Diabetes Care (2003) 3.37
The independent effect of type 2 diabetes mellitus on ischemic heart disease, stroke, and death: a population-based study of 13,000 men and women with 20 years of follow-up. Arch Intern Med (2004) 3.34
Weight change and diabetes incidence: findings from a national cohort of US adults. Am J Epidemiol (1997) 3.32
Obesity and cancer: the role of dysfunctional adipose tissue. Cancer Epidemiol Biomarkers Prev (2009) 3.25
Changes in weight, body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol (2001) 3.23
Metabolic syndrome, hyperinsulinemia, and colon cancer: a review. Am J Clin Nutr (2007) 3.20
Adult weight change and risk of postmenopausal breast cancer. JAMA (2006) 3.11
Exercise or exercise and diet for preventing type 2 diabetes mellitus. Cochrane Database Syst Rev (2008) 3.11
The dose-effect relationship between 'unopposed' oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br J Cancer (1988) 3.07
Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA (2011) 3.02
Obesity and cancer. Oncologist (2010) 3.01
Obesity and cancer. Oncogene (2004) 3.01
Biological mechanisms linking obesity and cancer risk: new perspectives. Annu Rev Med (2010) 2.94
The gastric bypass operation reduces the progression and mortality of non-insulin-dependent diabetes mellitus. J Gastrointest Surg (2006) 2.93
Overweight as an avoidable cause of cancer in Europe. Int J Cancer (2001) 2.88
Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res (2011) 2.85
Macrophages induce invasiveness of epithelial cancer cells via NF-kappa B and JNK. J Immunol (2005) 2.81
The glycemic index: not the most effective nutrition therapy intervention. Diabetes Care (2003) 2.78
The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. Cancer Res (2007) 2.71
The cost of obesity in Canada. CMAJ (1999) 2.71
A prospective study of weight change and health-related quality of life in women. JAMA (1999) 2.60
Body mass index and adenocarcinomas of the esophagus or gastric cardia: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev (2006) 2.59
Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study. J Clin Oncol (2005) 2.57
Effects of weight loss on regional fat distribution and insulin sensitivity in obesity. Diabetes (1999) 2.48
Intensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose tolerance. Diabetes (2005) 2.46
Obesity, inactivity, and the prevalence of diabetes and diabetes-related cardiovascular comorbidities in the U.S., 2000-2002. Diabetes Care (2005) 2.44
Obesity and hepatocellular carcinoma. Gastroenterology (2004) 2.38
High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes. Diabetes (2002) 2.36
Undertreatment of obese women receiving breast cancer chemotherapy. Arch Intern Med (2005) 2.25
Body mass index and pancreatic cancer risk: A meta-analysis of prospective studies. Int J Cancer (2007) 2.22
Weight change and duration of overweight and obesity in the incidence of type 2 diabetes. Diabetes Care (1999) 2.20
Central obesity and breast cancer risk: a systematic review. Obes Rev (2003) 2.16
A prospective study of C-peptide, insulin-like growth factor-I, insulin-like growth factor binding protein-1, and the risk of colorectal cancer in women. Cancer Epidemiol Biomarkers Prev (2005) 2.15
Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS Intervention Study. Obes Res (1999) 2.11
Obesity and cancer. Proc Nutr Soc (2008) 2.00
Body mass index history and risk of type 2 diabetes: results from the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Am J Clin Nutr (2006) 1.98
Obesity and prostate cancer: making sense out of apparently conflicting data. Epidemiol Rev (2007) 1.97
Sleeve gastrectomy and type 2 diabetes mellitus: a systematic review. Surg Obes Relat Dis (2010) 1.95
The magnitude of association between overweight and obesity and the risk of diabetes: a meta-analysis of prospective cohort studies. Diabetes Res Clin Pract (2010) 1.94
Lack of association of physical activity and obesity with incident pancreatic cancer in elderly women. Cancer Epidemiol Biomarkers Prev (2005) 1.92
Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. Diabetes Care (2003) 1.91
Risk factors for renal cell cancer: the multiethnic cohort. Am J Epidemiol (2007) 1.87
Obesity and thyroid cancer risk among U.S. men and women: a pooled analysis of five prospective studies. Cancer Epidemiol Biomarkers Prev (2011) 1.86
Obesity in the Pima Indians: its magnitude and relationship with diabetes. Am J Clin Nutr (1991) 1.77
Obesity and insulin resistance in humans: a dose-response study. Metabolism (1990) 1.74
The cell growth suppressor, mir-126, targets IRS-1. Biochem Biophys Res Commun (2008) 1.73
Obesity and cancer: the risks, science, and potential management strategies. Oncology (Williston Park) (2005) 1.72
Overall obesity, abdominal adiposity, diabetes and cigarette smoking in relation to the risk of pancreatic cancer in two Swedish population-based cohorts. Br J Cancer (2005) 1.71
A high concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of NIDDM. Diabetologia (1995) 1.70
Caloric restriction per se is a significant factor in improvements in glycemic control and insulin sensitivity during weight loss in obese NIDDM patients. Diabetes Care (1994) 1.67
Temporal trends in BMI among adults with diabetes. Diabetes Care (2001) 1.64
Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? Hepatology (2002) 1.63
Association of visceral fat accumulation and plasma adiponectin with colorectal adenoma: evidence for participation of insulin resistance. Clin Cancer Res (2005) 1.61
Body size and composition and colon cancer risk in men. Cancer Epidemiol Biomarkers Prev (2004) 1.59
Mechanisms of disease: adipokines and breast cancer - endocrine and paracrine mechanisms that connect adiposity and breast cancer. Nat Clin Pract Endocrinol Metab (2007) 1.56
Weight change and risk of postmenopausal breast cancer (United States). Cancer Causes Control (2000) 1.56
Effects of fat on glucose uptake and utilization in patients with non-insulin-dependent diabetes. J Clin Invest (1995) 1.47
Absolute fat mass, percent body fat, and body-fat distribution: which is the real determinant of blood pressure and serum glucose? Am J Clin Nutr (1992) 1.47
Relationship of generalized and regional adiposity to insulin sensitivity in men with NIDDM. Diabetes (1996) 1.43
Hepatic hyperplasia in noncirrhotic fatty livers: is obesity-related hepatic steatosis a premalignant condition? Cancer Res (2001) 1.42
Effects of weight loss on mechanisms of hyperglycemia in obese non-insulin-dependent diabetes mellitus. Diabetes (1986) 1.41
Metformin: an update. Ann Intern Med (2002) 5.62
Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med (2003) 4.08
Sleep duration among black and white Americans: results of the National Health Interview Survey. J Natl Med Assoc (2008) 3.82
Role of mitochondrial dysfunction in insulin resistance. Circ Res (2008) 3.45
Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med (2009) 2.25
Awareness of kidney disease and relationship to end-stage renal disease and mortality. Am J Med (2012) 2.24
Prevalence of CKD and comorbid illness in elderly patients in the United States: results from the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis (2010) 2.18
Hypertension, angiotensin II, and oxidative stress. N Engl J Med (2002) 1.92
Mitochondrial biogenesis in the metabolic syndrome and cardiovascular disease. J Mol Med (Berl) (2010) 1.90
Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol (2004) 1.73
CKD in the United States: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis (2008) 1.71
Renin-angiotensin-aldosterone system and oxidative stress in cardiovascular insulin resistance. Am J Physiol Heart Circ Physiol (2007) 1.71
Bariatric surgery reduces visceral adipose inflammation and improves endothelial function in type 2 diabetic mice. Arterioscler Thromb Vasc Biol (2011) 1.69
Osteoporosis and cardiovascular disease: brittle bones and boned arteries, is there a link? Endocrine (2004) 1.64
Adverse effects of phytoestrogens on reproductive health: a report of three cases. Complement Ther Clin Pract (2008) 1.62
Angiotensin II-induced NADPH oxidase activation impairs insulin signaling in skeletal muscle cells. J Biol Chem (2006) 1.62
The case for low carbohydrate diets in diabetes management. Nutr Metab (Lond) (2005) 1.61
Effect of antihypertensive agents on the development of type 2 diabetes mellitus. Mayo Clin Proc (2006) 1.60
Vascular ossification-calcification in metabolic syndrome, type 2 diabetes mellitus, chronic kidney disease, and calciphylaxis-calcific uremic arteriolopathy: the emerging role of sodium thiosulfate. Cardiovasc Diabetol (2005) 1.59
Control of cardiovascular risk factors in patients with diabetes and hypertension at urban academic medical centers. Diabetes Care (2002) 1.59
AT1 blockade prevents glucose-induced cardiac dysfunction in ventricular myocytes: role of the AT1 receptor and NADPH oxidase. Hypertension (2003) 1.57
Diabetes mellitus and CKD awareness: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES). Am J Kidney Dis (2009) 1.52
Cholestatic hepatitis C following liver transplantation: an outcome-based histological definition, clinical predictors, and prognosis. Liver Transpl (2013) 1.52
Control of blood pressure and other cardiovascular risk factors at different practice settings: outcomes of care provided to diabetic women compared to men. J Clin Hypertens (Greenwich) (2005) 1.51
ASH position paper: treatment of hypertension in patients with diabetes-an update. J Clin Hypertens (Greenwich) (2008) 1.50
Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in older vs younger patients with hypertension uncontrolled with monotherapy. Am J Geriatr Cardiol (2008) 1.48
Epidemiology of diabetes. J Clin Pharmacol (2004) 1.47
Angiotensin II-mediated oxidative stress promotes myocardial tissue remodeling in the transgenic (mRen2) 27 Ren2 rat. Am J Physiol Endocrinol Metab (2007) 1.46
Redox control of renal function and hypertension. Antioxid Redox Signal (2008) 1.45
Mineralocorticoid receptor-mediated vascular insulin resistance: an early contributor to diabetes-related vascular disease? Diabetes (2013) 1.45
Dietary carbohydrate restriction in type 2 diabetes mellitus and metabolic syndrome: time for a critical appraisal. Nutr Metab (Lond) (2008) 1.44
Skeletal muscle insulin resistance: role of inflammatory cytokines and reactive oxygen species. Am J Physiol Regul Integr Comp Physiol (2007) 1.39
No independent association of serum phosphorus with risk for death or progression to end-stage renal disease in a large screen for chronic kidney disease. Kidney Int (2013) 1.38
Obstructive sleep apnea and cardiovascular disease: role of the metabolic syndrome and its components. J Clin Sleep Med (2008) 1.38
CKD and cardiovascular disease in screened high-risk volunteer and general populations: the Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis (2008) 1.37
Angiotensin II-induced skeletal muscle insulin resistance mediated by NF-kappaB activation via NADPH oxidase. Am J Physiol Endocrinol Metab (2007) 1.36
The Role of Overweight and Obesity in the Cardiorenal Syndrome. Cardiorenal Med (2011) 1.35
Abrogation of oxidative stress improves insulin sensitivity in the Ren-2 rat model of tissue angiotensin II overexpression. Am J Physiol Endocrinol Metab (2004) 1.33
NADPH oxidase contributes to vascular inflammation, insulin resistance, and remodeling in the transgenic (mRen2) rat. Hypertension (2007) 1.32
Nebivolol improves diastolic dysfunction and myocardial remodeling through reductions in oxidative stress in the Zucker obese rat. Hypertension (2010) 1.32
Mineralocorticoid receptor blockade attenuates chronic overexpression of the renin-angiotensin-aldosterone system stimulation of reduced nicotinamide adenine dinucleotide phosphate oxidase and cardiac remodeling. Endocrinology (2007) 1.31
Race/ethnicity, sleep duration, and diabetes mellitus: analysis of the National Health Interview Survey. Am J Med (2012) 1.31
Erythropoietin protects cardiac myocytes from hypoxia-induced apoptosis through an Akt-dependent pathway. Biochem Biophys Res Commun (2003) 1.31
Oxidative stress and glomerular filtration barrier injury: role of the renin-angiotensin system in the Ren2 transgenic rat. Am J Physiol Renal Physiol (2006) 1.30
The metabolic syndrome: role of skeletal muscle metabolism. Ann Med (2006) 1.28
Maladaptive immune and inflammatory pathways lead to cardiovascular insulin resistance. Metabolism (2013) 1.27
Activation of mTOR/p70S6 kinase by ANG II inhibits insulin-stimulated endothelial nitric oxide synthase and vasodilation. Am J Physiol Endocrinol Metab (2011) 1.25
The role of oxidative stress in the metabolic syndrome. Rev Cardiovasc Med (2011) 1.23
Attenuation of NADPH oxidase activation and glomerular filtration barrier remodeling with statin treatment. Hypertension (2008) 1.23
Association of diabetes and hepatitis C infection: epidemiologic evidence and pathophysiologic insights. Curr Diab Rep (2004) 1.22
Low-dose spironolactone reduces reactive oxygen species generation and improves insulin-stimulated glucose transport in skeletal muscle in the TG(mRen2)27 rat. Am J Physiol Endocrinol Metab (2008) 1.22
Renin inhibition attenuates insulin resistance, oxidative stress, and pancreatic remodeling in the transgenic Ren2 rat. Endocrinology (2008) 1.21
Molecular and metabolic mechanisms of cardiac dysfunction in diabetes. Life Sci (2012) 1.21
Hypertension and obesity. Recent Prog Horm Res (2004) 1.20
Role of insulin resistance in endothelial dysfunction. Rev Endocr Metab Disord (2013) 1.19
Obesity and insulin resistance induce early development of diastolic dysfunction in young female mice fed a Western diet. Endocrinology (2013) 1.19
Sleep in America: role of racial/ethnic differences. Sleep Med Rev (2013) 1.19
Differential regulation of angiotensin-(1-12) in plasma and cardiac tissue in response to bilateral nephrectomy. Am J Physiol Heart Circ Physiol (2009) 1.18
Direct renin inhibition improves systemic insulin resistance and skeletal muscle glucose transport in a transgenic rodent model of tissue renin overexpression. Endocrinology (2009) 1.18
The relationship between hyperinsulinemia, hypertension and progressive renal disease. J Am Soc Nephrol (2004) 1.16
Calciphylaxis: calcific uremic arteriolopathy and the emerging role of sodium thiosulfate. Int Urol Nephrol (2008) 1.16
Extreme sleep durations and increased C-reactive protein: effects of sex and ethnoracial group. Sleep (2013) 1.16
Prevalence and associations of anemia of CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004. Am J Kidney Dis (2008) 1.16
Dipeptidylpeptidase inhibition is associated with improvement in blood pressure and diastolic function in insulin-resistant male Zucker obese rats. Endocrinology (2013) 1.15
Effect of renin inhibition and AT1R blockade on myocardial remodeling in the transgenic Ren2 rat. Am J Physiol Endocrinol Metab (2008) 1.15
Sleep duration and the risk of diabetes mellitus: epidemiologic evidence and pathophysiologic insights. Curr Diab Rep (2010) 1.14
The central role of vascular extracellular matrix and basement membrane remodeling in metabolic syndrome and type 2 diabetes: the matrix preloaded. Cardiovasc Diabetol (2005) 1.14
The renin angiotensin aldosterone system in hypertension: roles of insulin resistance and oxidative stress. Med Clin North Am (2009) 1.13
Salt, aldosterone, and insulin resistance: impact on the cardiovascular system. Nat Rev Cardiol (2010) 1.13
Diabetes mellitus in CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition and Examination Survey (NHANES) 1999-2004. Am J Kidney Dis (2008) 1.12
Oxidative stress contributes to pulmonary hypertension in the transgenic (mRen2)27 rat. Am J Physiol Heart Circ Physiol (2008) 1.12
Adaptive mechanisms to compensate for overnutrition-induced cardiovascular abnormalities. Am J Physiol Regul Integr Comp Physiol (2011) 1.12
Oxidative stress, glucose metabolism, and the prevention of type 2 diabetes: pathophysiological insights. Antioxid Redox Signal (2007) 1.12
Aldosterone: role in the cardiometabolic syndrome and resistant hypertension. Prog Cardiovasc Dis (2010) 1.12
IGF-I alleviates diabetes-induced RhoA activation, eNOS uncoupling, and myocardial dysfunction. Am J Physiol Regul Integr Comp Physiol (2008) 1.11
Rosuvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, decreases cardiac oxidative stress and remodeling in Ren2 transgenic rats. Endocrinology (2007) 1.11
Hypertension in obesity. Med Clin North Am (2011) 1.10
Mechanisms by which angiotensin-converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am J Cardiol (2003) 1.09
Heart disease in diabetic patients. Curr Diab Rep (2003) 1.09